Exactech selects MMI to evaluate novel cartilage repair treatment

Apr 19 2012

Medical Metrics Inc, (MMI), an experienced provider of medical imaging core lab services for global clinical trials, has been selected by Exactech, Inc. to conduct an independent evaluation of medical images from the BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial approved by the Taiwan FDA. This prospective, randomized study will be conducted in Taiwan to evaluate a novel cartilage repair treatment. The biphasic implant is a two-phase scaffold that is intended to promote integration with subchondral bone and regeneration of hyaline-like cartilage. During the study, MMI will provide comprehensive analysis and management of MR images.    

MMI developed the imaging sequences and assessment panels necessary to evaluate treatment outcomes, including extent of lesion repair, bone-implant integration, and overall device integrity. Matt Christensen, Exactech's Director of Clinical Affairs, said "We chose Medical Metrics for their extensive expertise in musculoskeletal imaging and cartilage repair. MMI is a valuable resource for clinical input on study design, and their commitment to customer services is impressive."

Exactech's BiCRI IDE trial supports the company's corporate objective to enter the cartilage repair market and commercialize the new technology in multiple global markets. MMI has supported osteoarthritis (OA) trials of treatments for cartilage repair and replacement since 2000. Nick Wharton, MMI's SVP of Technical Services, commented, "Sponsors benefit from our broad experience in OA clinical trials and unique clinical and scientific expertise. We are proud to have been selected by Exactech as the imaging core lab for this important pivotal trial."

Source: Medical Metrics